Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

5.7K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K
Positive Regulator Molecules02:39

Positive Regulator Molecules

5.6K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.6K
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

2.9K
The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
2.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diversity in CDK structural mechanisms of regulation and drug discovery opportunities.

Trends in biochemical sciences·2026
Same author

Covalent Alkynylpyridopyrimidinones Targeting Cysteine 775 of the Epidermal Growth Factor Receptor Overcome Resistance to Current Therapies.

Journal of medicinal chemistry·2025
Same author

Crystallographic fragment screening of CDK2-cyclin A: FragLites map sites of protein-protein interaction.

Structure (London, England : 1993)·2025
Same author

Nanobodies restore stability to cancer-associated mutants of tumor suppressor protein p16<sup>INK4a</sup>.

Structure (London, England : 1993)·2025
Same author

Different applications and differentiated libraries for crystallographic fragment screening.

Current opinion in structural biology·2025
Same author

Structural requirements for the specific binding of CRABP2 to cyclin D3.

Structure (London, England : 1993)·2024

Related Experiment Video

Updated: Aug 9, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K

Emerging approaches to CDK inhibitor development, a structural perspective.

Ian Hope1, Jane A Endicott1, Jessica E Watt1

  • 1Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Paul O'Gorman Building, Framlington Place Newcastle upon Tyne NE2 4HH UK Jessica.Watt@newcastle.ac.uk.

RSC Chemical Biology
|February 16, 2023
PubMed
Summary
This summary is machine-generated.

Targeting cyclin-dependent kinases (CDKs) is crucial for disease treatment. Novel CDK inhibitors are needed due to specificity issues with current ATP-binding site drugs, exploring allosteric inhibition and degradation strategies.

More Related Videos

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay
12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

18.7K
Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach
11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

7.5K

Related Experiment Videos

Last Updated: Aug 9, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K
Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay
12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

18.7K
Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach
11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

7.5K

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Drug Discovery

Background:

  • Aberrant cyclin-dependent kinase (CDK) activity is implicated in various diseases, making CDKs attractive drug targets.
  • Current CDK inhibitors often lack specificity due to conserved ATP-binding clefts across the CDK family.
  • Novel inhibition strategies are essential for developing effective CDK-targeted therapies.

Purpose of the Study:

  • To review recent advances in understanding CDK structure, function, and inhibition mechanisms.
  • To explore novel approaches for CDK inhibitor design beyond traditional ATP-competitive inhibition.
  • To highlight the potential of allosteric inhibition and chemical degradation for targeted CDK therapies.

Main Methods:

  • Review of structural data from X-ray crystallography and cryo-electron microscopy of CDK complexes.
  • Analysis of conformational malleability and Short Linear Motif (SLiM) recognition in CDK regulation.
  • Exploration of fragment-based drug discovery for allosteric site identification.

Main Results:

  • Recent structural studies provide deeper insights into CDK functional roles and regulatory mechanisms.
  • Identification of allosteric sites and native protein-protein interaction mimics for small molecule binding.
  • Progress in chemically induced CDK degradation offers a new therapeutic avenue.

Conclusions:

  • Structural insights are crucial for designing specific CDK inhibitors.
  • Allosteric inhibition and targeted protein degradation represent promising strategies for novel CDK therapies.
  • Understanding CDK conformational dynamics and interaction sites is key to advancing targeted treatments.